Browse the corpus
Walk the Even Hospital Database by book and chapter — the raw source passages that ground Ask, DDx, and the rest.
1 passage
REFERENCES Bezalip® SR product monograph, ACTAVIS Group PTC ehf, Iceland, May 2008 Ericsson CG, Nilsson J, Grip L, et al, “Effect of Bezafibrate Treatment Over Five Years on Coronary Plaques Causing 20% to 50% Diameter Narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]),” Am J Cardiol , 1997, 80(9):1125-9. [PubMed 9359536 ] “Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),” JAMA , 2001, 285(19):2486-97. [PubMed 11368702 ] Genest J, McPherson R, Frohlich J, et al, “2009 Canadian Cardiovascular Society/Canadian Guidelines for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease in the Adult – 2009 Recommendations,” Can J Cardiol , 2009, 25(10):567-79. [PubMed 19812802 ] McPherson R, Frohlich J, Fodor G, et al, “Canadian Cardiovascular Society Position Statement--Recommendations for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease,” Can J Cardiol , 2006, 22(11):913-27; published erratum appears in Can J Cardiol , 2006, 22(12):1077. [PubMed 16971976 ] “Secondary Prevention by Raising HDL Cholesterol and Reducing Triglycerides in Patients With Coronary Artery Disease: The Bezafibrate Infarction Prevention (BIP) Study. The BIP Study Group,” Circulation , 2000, 102(1):21-7 [PubMed 10880410 ] Topic 8696 Version 35.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [0504-125.39.66.147-70BC344B75-S244013.14]